Stifel Appointed as Financial Advisor for Santhera Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy SF?
Source: Yahoo Finance
Stifel Financial Corp shares fell sharply, hitting a 20-day low amid broader market weakness, with the Nasdaq-100 down 1.60% and the S&P 500 down 1.04%.
Santhera Pharmaceuticals has appointed Stifel Nicolaus Europe Limited as its new corporate finance advisor, focusing on capital markets and international institutional investors. This partnership aims to enhance Santhera's visibility and attractiveness in the global market, particularly as it develops innovative medicines for rare neuromuscular diseases, including AGAMREE® (vamorolone), which has received approvals in multiple regions. The collaboration with Octavian AG will further broaden the investor base.
The appointment of Stifel as an advisor reflects the company's strategic positioning in the capital markets, although the current market conditions have led to a decline in Stifel's stock price. Investors will be watching closely how this partnership impacts Santhera's growth and market presence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SF
Wall Street analysts forecast SF stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 120.490
Low
133.00
Averages
143.67
High
155.00
Current: 120.490
Low
133.00
Averages
143.67
High
155.00
About SF
Stifel Financial Corp. is a financial holding company. The Company's principal subsidiary is Stifel, Nicolaus & Company, Incorporated, a full-service retail and institutional wealth management and investment banking company. The Company’s segments include Global Wealth Management, Institutional Group, and Other. Its Global Wealth Management segment provides securities transaction, brokerage, and investment services to its clients through the consolidated Stifel branch system. The Institutional Group segment includes research, equity and fixed income institutional sales and trading, investment banking, public finance, and syndicate. The Other segment includes interest income from stock borrowing activities, unallocated interest expense, interest income and gains and losses from investments held, amortization of stock-based awards for certain administrative associates; and all unallocated overhead costs associated with the execution of orders; custody of client securities, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inspire Medical Systems Faces Near-Term Challenges
- Price Target Reduction: Stifel lowered its price target for Inspire Medical Systems from $110 to $95 while maintaining a Buy rating, indicating ongoing reimbursement challenges that impact the company's operations and billing environment.
- Profitability Constraints: Although Inspire's projected revenue growth for 2026 remains in the high single digits, the implementation of a new CPT code could reduce physician payments by 10%-50%, potentially slowing procedure volumes and new account growth, thereby affecting future performance.
- Widespread Rating Downgrades: Baird and Wells Fargo downgraded Inspire's ratings to Neutral and Equal Weight, respectively, citing uncertainty around physician reimbursements and a weaker growth outlook for 2026, which raises concerns about the company's future performance.
- Strong Financial Performance: Despite challenges, Inspire reported a 12% year-over-year revenue increase in Q4, with earnings of $1.65 per share exceeding expectations and margins improving to 17.5%, demonstrating the company's potential for profitability amidst headwinds.
See More
Centrus Energy Shares Recover as Analysts Remain Bullish
- Price Recovery: Centrus Energy shares have risen by 7% to $13.20, returning to early September levels, indicating a resurgence of investor confidence and positioning the stock to end the week positively.
- Analyst Support: Despite Centrus's recent earnings report failing to meet revenue and profit expectations, leading to some sell-offs, analysts remain optimistic, with JPMorgan lowering its price target to $236, still implying over 12% upside potential.
- Strong Backlog: With a robust $3.8 billion backlog, Centrus is well-positioned to thrive amid the ongoing nuclear renaissance, showcasing consistent profitability despite short-term challenges.
- Market Reaction: Supported by analysts, investor buying interest in Centrus has increased, reflecting strong confidence in the company's future growth potential, even after missing expectations.
See More
Air Canada Reports Strong Q4 Earnings
- Earnings Beat: Air Canada reported a 15% EBITDA beat in Q4, indicating significant progress in recovering flight demand and enhancing operational efficiency, which further solidifies its market position.
- Revenue Growth: While specific revenue figures were not disclosed, the overall strong performance suggests that the airline successfully attracted more passengers in a competitive market, likely boosting future profitability.
- Operational Efficiency: By optimizing routes and enhancing customer service, Air Canada significantly improved operational efficiency in Q4, which not only enhances customer satisfaction but may also reduce operating costs, thereby improving overall profitability.
- Positive Market Outlook: With the global travel demand recovering, Air Canada's strong performance lays a solid foundation for future growth, and it is expected to continue benefiting from the resurgence of the travel industry and rising consumer confidence.
See More
Axalta and PPG Report Fourth Quarter Earnings
- Earnings Report: Axalta and PPG, the two largest suppliers in the collision-repair paint industry, have reported their fourth-quarter earnings, although specific financial figures were not disclosed, the market is keenly observing their performance impact on the industry.
- Market Reaction: Investor responses to the earnings of both companies could influence overall confidence in the paint industry, particularly in the current economic climate where recovery prospects are under scrutiny.
- Competitive Dynamics: The performance of Axalta and PPG will serve as a benchmark for other paint suppliers, potentially triggering strategic adjustments within the industry that could affect market share distribution.
- Future Outlook: As the automotive repair market gradually recovers, the earnings performance of Axalta and PPG will be a critical indicator of industry recovery, prompting investors to closely monitor subsequent developments.
See More
Mixed Close for US Stocks as Retail Sales Stagnate
- Retail Sales Weakness: US December retail sales were unchanged month-over-month, falling short of the +0.4% expectation, indicating weakness in consumer spending that could lead to a downward revision in Q4 GDP, thereby impacting market confidence and economic growth outlook.
- Employment Cost Index Decline: The US Q4 employment cost index rose by +0.7% quarter-over-quarter, below the expected +0.8%, marking the smallest increase in 4.5 years, suggesting easing labor cost pressures that may influence the Fed's monetary policy decisions.
- Mixed Market Performance: The Dow Jones Industrial Average reached a new all-time high, closing up +0.10%, while the S&P 500 and Nasdaq 100 indices fell by -0.33% and -0.56%, respectively, reflecting divergent market sentiment and uncertainty.
- Focus on Upcoming Economic Data: The market will closely monitor upcoming economic data, including January nonfarm payrolls and unemployment rate, which are expected to significantly influence future monetary policy and market trends.
See More
Wealth Management Startup Triggers Market Turmoil
- Market Reaction: Shares of U.S. brokerages fell sharply after wealth management startup Altruist launched AI-enabled tax planning features, with Charles Schwab (SCHW.N) down 6.4% and LPL Financial (LPLA.O) diving 8.3%, indicating growing investor anxiety towards traditional financial firms.
- Disruption Concerns: The rise of AI-first startups automating complex tasks has heightened investor fears about the future of legacy financial and tech companies, particularly as Altruist's new features threaten to disrupt retail brokerage operations.
- Market Dynamics: Morgan Stanley (MS.N) fell 2.8% and Ameriprise Financial (AMP.N) slipped 6%, reflecting the broader financial market's turmoil following a selloff in global software stocks due to concerns over disruptive technologies.
- Intensifying Competition: Altruist's Hazel AI platform automates personalized tax strategy creation by analyzing client documents, posing a threat to retail brokerages, especially as insurgent firms like Robinhood and Public have already made inroads with low-cost, tech-enabled offerings.
See More
Inspire Medical Systems Faces Near-Term Challenges
- Price Target Reduction: Stifel lowered its price target for Inspire Medical Systems from $110 to $95 while maintaining a Buy rating, indicating ongoing reimbursement challenges that impact the company's operations and billing environment.
- Profitability Constraints: Although Inspire's projected revenue growth for 2026 remains in the high single digits, the implementation of a new CPT code could reduce physician payments by 10%-50%, potentially slowing procedure volumes and new account growth, thereby affecting future performance.
- Widespread Rating Downgrades: Baird and Wells Fargo downgraded Inspire's ratings to Neutral and Equal Weight, respectively, citing uncertainty around physician reimbursements and a weaker growth outlook for 2026, which raises concerns about the company's future performance.
- Strong Financial Performance: Despite challenges, Inspire reported a 12% year-over-year revenue increase in Q4, with earnings of $1.65 per share exceeding expectations and margins improving to 17.5%, demonstrating the company's potential for profitability amidst headwinds.
See More
Centrus Energy Shares Recover as Analysts Remain Bullish
- Price Recovery: Centrus Energy shares have risen by 7% to $13.20, returning to early September levels, indicating a resurgence of investor confidence and positioning the stock to end the week positively.
- Analyst Support: Despite Centrus's recent earnings report failing to meet revenue and profit expectations, leading to some sell-offs, analysts remain optimistic, with JPMorgan lowering its price target to $236, still implying over 12% upside potential.
- Strong Backlog: With a robust $3.8 billion backlog, Centrus is well-positioned to thrive amid the ongoing nuclear renaissance, showcasing consistent profitability despite short-term challenges.
- Market Reaction: Supported by analysts, investor buying interest in Centrus has increased, reflecting strong confidence in the company's future growth potential, even after missing expectations.
See More
Air Canada Reports Strong Q4 Earnings
- Earnings Beat: Air Canada reported a 15% EBITDA beat in Q4, indicating significant progress in recovering flight demand and enhancing operational efficiency, which further solidifies its market position.
- Revenue Growth: While specific revenue figures were not disclosed, the overall strong performance suggests that the airline successfully attracted more passengers in a competitive market, likely boosting future profitability.
- Operational Efficiency: By optimizing routes and enhancing customer service, Air Canada significantly improved operational efficiency in Q4, which not only enhances customer satisfaction but may also reduce operating costs, thereby improving overall profitability.
- Positive Market Outlook: With the global travel demand recovering, Air Canada's strong performance lays a solid foundation for future growth, and it is expected to continue benefiting from the resurgence of the travel industry and rising consumer confidence.
See More
Axalta and PPG Report Fourth Quarter Earnings
- Earnings Report: Axalta and PPG, the two largest suppliers in the collision-repair paint industry, have reported their fourth-quarter earnings, although specific financial figures were not disclosed, the market is keenly observing their performance impact on the industry.
- Market Reaction: Investor responses to the earnings of both companies could influence overall confidence in the paint industry, particularly in the current economic climate where recovery prospects are under scrutiny.
- Competitive Dynamics: The performance of Axalta and PPG will serve as a benchmark for other paint suppliers, potentially triggering strategic adjustments within the industry that could affect market share distribution.
- Future Outlook: As the automotive repair market gradually recovers, the earnings performance of Axalta and PPG will be a critical indicator of industry recovery, prompting investors to closely monitor subsequent developments.
See More
Mixed Close for US Stocks as Retail Sales Stagnate
- Retail Sales Weakness: US December retail sales were unchanged month-over-month, falling short of the +0.4% expectation, indicating weakness in consumer spending that could lead to a downward revision in Q4 GDP, thereby impacting market confidence and economic growth outlook.
- Employment Cost Index Decline: The US Q4 employment cost index rose by +0.7% quarter-over-quarter, below the expected +0.8%, marking the smallest increase in 4.5 years, suggesting easing labor cost pressures that may influence the Fed's monetary policy decisions.
- Mixed Market Performance: The Dow Jones Industrial Average reached a new all-time high, closing up +0.10%, while the S&P 500 and Nasdaq 100 indices fell by -0.33% and -0.56%, respectively, reflecting divergent market sentiment and uncertainty.
- Focus on Upcoming Economic Data: The market will closely monitor upcoming economic data, including January nonfarm payrolls and unemployment rate, which are expected to significantly influence future monetary policy and market trends.
See More
Wealth Management Startup Triggers Market Turmoil
- Market Reaction: Shares of U.S. brokerages fell sharply after wealth management startup Altruist launched AI-enabled tax planning features, with Charles Schwab (SCHW.N) down 6.4% and LPL Financial (LPLA.O) diving 8.3%, indicating growing investor anxiety towards traditional financial firms.
- Disruption Concerns: The rise of AI-first startups automating complex tasks has heightened investor fears about the future of legacy financial and tech companies, particularly as Altruist's new features threaten to disrupt retail brokerage operations.
- Market Dynamics: Morgan Stanley (MS.N) fell 2.8% and Ameriprise Financial (AMP.N) slipped 6%, reflecting the broader financial market's turmoil following a selloff in global software stocks due to concerns over disruptive technologies.
- Intensifying Competition: Altruist's Hazel AI platform automates personalized tax strategy creation by analyzing client documents, posing a threat to retail brokerages, especially as insurgent firms like Robinhood and Public have already made inroads with low-cost, tech-enabled offerings.
See More
